Fresenius医疗保健一次养育一名患者

A man of science, Benjamin Lipps, chief executive officer of Fresenius Medical Care, a provider of products and services for patients with chronic kidney failure, spends much of his time focused on how to deliver better dialysis care to a growing number of patients around the world. His ability to accomplish this task, while also increasing the company’s revenues and profits every year since its founding in 1996 is what most impressed sell-side analysts, who voted Lipps best CEO in the medical technologies and services sector in Institutional Investors 2011 All-European Executive Team ranking. Both buy and sell side analysts voted the firm’s head of investor relations and corporate communications, Oliver Maier, as best IR Professional in the sector. Fresenius Medical Care also won Best Investor Relations outfit in its category.

Lipps, age 70, received his PhD in chemical engineering from the Massachusetts Institute of Technology in Cambridge, MA. He has worked in the field of dialysis for almost half a decade and was part of the research team at DOW Chemical, the Midland, MI- based chemical manufacturer that developed the first commercial hollow-fiber artificial kidney in 1966.

From 1985 to 1996, Lipps served as CEO of Fresenius USA, a Waltham, Massachusetts-based provider of kidney dialysis services and renal care products. He took on the role of CEO of Fresenius Medical Care North America in 1996, serving until 1999 when he became CEO and Chairman of the Management Board of the Bad Homburg, Germany-based parent company Fresenius Medical Care.

当Lipps开始他的实验室工作时，透析治疗并不存在。如今，弗雷斯尼乌斯医疗保健是世界上最大的提供商，市场份额为131亿欧元，截至2010年底，2009年上升了110.45亿欧元。该公司列入了法兰克福威尔·韦尔皮尔巴索（法兰克福证券交易所）和纽约证券交易所。

Lipps在透析治疗领域的成就 - 他的办公室坐在透析单元上 - 结合他敏锐的商业意识，只帮助了公司。并增长它。2011年1月4日Fresenius医疗保健为485万欧元签署了485万欧元的购买协议，以获得国际透析中心，Euromedic International的透析服务业务，泛欧医疗服务提供商。在协议之前，Fresenius医疗保健在东欧市场上有一个小立足点，并且一直在寻找增加其存在的方法。相比之下，Euromedic正在寻求一种方法来卸载其血液透析业务，专注于诊断和癌症治疗。

Fresenius医疗预计欧洲教育收购预计将增加约1.5亿美元的收入，并预测第一年的收益将受到累积。该交易计划于2011年第二季度关闭。

Fresenius医疗保健最初将使用当前运营的现金流量和公司可用的借贷能力来融资收购。“今年，我们汇率超过了我们的银行债务，基本上债券，达到约10亿美元（6.5亿美元和3亿欧元），因此将初始融资置于”Lipps“。结束后，它将在长期的基础上进行再融资。

Due to the worldwide financial crisis, touched off in 2008, with the collapse of U.S.-investment bank Lehman Brothers, many corporations have been looking for ways to downsize over the last couple years in response to a drop in revenue. Not so at Fresenius Medical Care. The lagging economy has had little effect on the need for medical attention worldwide, says Lipps. He made sure to impress this fact upon investors. “Because we are a global company, we needed to spend time with shareholders to point out the uniqueness of our business,” he says. Dialysis is “a disease of age” and as the world population continues to age and live longer, the need for dialysis should only increase, he notes. “For this reason, our business is insulated from the financial gyrations taking place around world.”

Lipps does concede that in certain area, such as the Asia Pacific region, there has been a lack of treatment for liver disease due to deep economic and financial hardship in that part of the world. But as the financial situation in many of those countries improves, Lipps believes that treatment of the disease will start to be addressed and therefore increase.

LIPPS预测，接受透析治疗的患者的数量应以5％的增长率为5％至6％。这意味着到2020年，400万人可以接受透析处理，从目前的200万。事实上，该公司在2010年最强大的收入增长领域在亚太地区，收入增长了15％。来自欧洲地区的收入在恒定货币和7％的北美占据了6％。

In February of this year, Fresenius Medical Care pleased shareholders again, when it announced it had exceeded its 2010 net revenue guidance by $50 million, finishing the year up 7 percent at $12 billion, compared to $11.2 billion in 2009. The company’s targeted net income of $950 to $980 million achieved the high end, finishing the year up 10 percent at $979 million.

Those stellar returns resulted in the company’s decision, pending shareholders approval in May 2011, to increase its dividend payout by 7 percent to 65 cents per share – marking the 14th consecutive dividend increase from the firm. “We have a dividend policy where we try to return to shareholders about 50 percent increase of net income,” notes Lipps. Looking ahead, the dialysis provider expects to see revenue growth in Asia rise by 10 percent to 15 percent, due to its dense population and expects single digit growth in North America.

In an effort to keep investors informed of the company’s ongoing growth strategy, Lipps spends about 20 percent of his time meeting with shareholders, often in one-to-one meetings or joined by Maier and the company’s chief financial officer Michael Brosnan. “We believe it is more important to do one-to-one meetings, face-to-face for 30 minutes,” says Lipps. “It takes time, but it’s worthwhile in the end, because we have a well informed long-term shareholders base.”

在美国，在美国，欧洲和一个在日本东京的欧洲和一年中，三人组参与了25个会议。“我们有一个全球股东基地，所以我们花了很多时间对股东活动，因为他们的问题永远不一样，”Lipps笔记。大约三分之一的公司投资者基于美国，在英国三分之一，德国10％，其余遍布欧洲和亚洲。

Lipps对其公司的成功感到满意，并奖励股东的能力，但他感到担任公司在医疗领域的成就的奖励。“我很幸运能够为患者和时间随着时间的推移而留住生命的机会，这将成为一项业务，”他说。“这是正确的焦点，这是我们的业务，这就是我们最好的。”